Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMT003
- Development stage
- Preclinical
- Lead developer
- SirnaMed
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
SMT003 is a preclinical small interfering RNA (siRNA) therapeutic candidate developed by SirnaMed for the treatment of Non-Hodgkin Lymphoma (NHL). The drug is designed to silence the expression of SERPINB9 (Serpin Family B Member 9), an intracellular protein that acts as a potent inhibitor of Granzyme B. In many cancers, including certain lymphomas, overexpression of SERPINB9 allows malignant cells to evade apoptosis triggered by cytotoxic T lymphocytes and natural killer (NK) cells. By reducing SERPINB9 levels, SMT003 aims to restore the susceptibility of tumor cells to Granzyme B-mediated programmed cell death, thereby enhancing the efficacy of the host's anti-tumor immune response.
- Other names
- SERPINB9-siRNASERPINB-9-siRNASERPINB 9-siRNA
02
Targets
SERPINB9 (Serpin family B member 9)
Beyond the preview
Go deeper on SMT003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMT003.